What is SelectQuote's gross profit margin?

What is the market's earnings forecast for SelectQuote next quarter?

What factors drove the changes in SelectQuote's revenue and profit?

What guidance did SelectQuote's management provide for the next earnings period?

What were the key takeaways from SelectQuote’s earnings call?

Did SelectQuote beat or miss consensus estimates last quarter?

What is SelectQuote's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for SelectQuote year over year?

- **Revenue Growth**: Q2 revenue up 12% YoY to $537M, driven by 26% growth in Healthcare Services and 2% in Senior segments.
- **Profitability Challenges**: $40M EBITDA reduction from carrier marketing cuts and PBM reimbursement, updated FY26 EBITDA guidance $90M-$100M.
- **Strategic Wins**: New PBM agreement stabilizes reimbursement, $415M credit facility extends debt maturities to 2031, and operating cash flow expected to grow 20% YoY.
- **Operational Strength**: Senior EBITDA margin 39%, SelectRx reduces hospital days by 20%, and agent productivity 12% higher than 2 years ago.
- **Growth Drivers**: Healthcare Services targeting $40M-$50M EBITDA exit rate, and SelectRx's Kansas facility poised for scalable, efficient expansion.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue reached $537 million, up 12% YoY, driven by both Senior and Healthcare Services segments. Senior revenue grew 2% to $262 million, while Healthcare Services revenue surged 26% to $231 million.
- **Operational Efficiency**: Senior segment achieved near-record EBITDA margins of 39%, reflecting strong marketing efficiency ($326 cost per approved policy) and agent productivity. Agent retention remained above 90%, with new agents contributing despite a lower tenured mix.
- **Challenges and Adjustments**: A national carrier reduced strategic marketing spend by $20 million, and PBM reimbursement impacts added another $20 million, leading to a $40 million EBITDA reduction. Updated FY26 guidance: revenue $1.61B-$1.71B, EBITDA $90M-$100M.
- **Strategic Moves**: Announced a multiyear PBM agreement for improved reimbursement visibility and a $415M credit facility extending debt maturities to 2031, enhancing capital flexibility.
- **Cash Flow Focus**: Despite EBITDA headwinds, operating cash flow is expected to grow 20% YoY to $25M-$35M, driven by Healthcare Services and Senior segment efficiency.

**【CFO Financial Commentary】**
- **Segment Performance**: Senior EBITDA was $102 million (39% margin), Healthcare Services EBITDA grew 20%+ with $40M-$50M annualized exit rate, and Life Insurance EBITDA was $6 million (9% revenue growth).
- **Balance Sheet Strength**: New credit facility reduces leverage risk and provides liquidity for strategic opportunities, with potential 100bps interest rate reduction as leverage improves.
- **PBM Impact**: FY26 PBM headwinds are one-time, with improved visibility from the new agreement. Healthcare Services will focus on high-margin enrollments to maintain profitability.

**【Q&A Highlights】**
- **PBM Agreement**: New PBM deal provides cost-plus structure with stable reimbursement, reducing risk and aligning with industry trends toward GER (Gross to Expense Ratio).
- **Carrier Risk**: CEO expects limited carrier follow-through on marketing cuts, as SelectQuote's retention (33% recapture rate) and quality volume make it a critical partner.
- **2027 Positioning**: CMS rate notice challenges may persist, but SelectQuote's data-driven service model (e.g., 20% reduction in hospital days via SelectRx) positions it as a preferred partner.
- **Credit Facility Flexibility**: CFO emphasized using enhanced liquidity to invest in high-ROI areas like SelectRx, which has 17% member growth and 26% revenue growth despite cash flow prioritization.
- **Kansas Facility Scale**: SelectRx's Kansas facility can absorb incremental volume with existing machinery, and AI-driven workflow improvements aim to enhance efficiency and gross margins.

SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript

- **Revenue growth in Healthcare Services**: 13% year-over-year, driven by strong agent performance and data-driven strategies.
- **PBM reimbursement challenges**: Near-term headwinds but constructive discussions for long-term stability.
- **AEP season confidence**: SelectQuote well-positioned for another successful enrollment period.


**【Management Opening Remarks】**
- Consolidated revenue of $329 million for the quarter, up 13% year-over-year, driven by Healthcare Services growth and strong agent performance in Senior Medicare Advantage.
- Senior segment EBITDA loss of $21 million due to lower policy production and upfront investments in AEP readiness.
- Healthcare Services segment impacted by PBM reimbursement changes, with Q2 EBITDA expected to be breakeven.

**【CEO Commentary】**
- Senior business navigating SEP complexity with 32% fewer policies, but maintaining long-term confidence in AEP positioning.
- Healthcare Services segment facing near-term headwinds but reaffirming long-term growth trajectory.

**【CFO Commentary】**
- SelectRx PBM reimbursement changes impacting Q1 and Q2 results, with negotiations ongoing for a stable rate structure.
- Life Insurance business showing resilience despite near-term pressures.

**【Q&A Highlights】**
- SelectRx adherence programs improving policyholder retention and clinical outcomes.
- AEP season early results align with expectations, with agents performing well in a dynamic market.
- Healthcare Services segment expected to return to normalized rates in Q3, supporting long-term visibility.


SelectQuote, Inc. (SLQT) Q1 2026 Earnings Call Transcript

- **Revenue Growth**: $1.5 billion FY2025 (+16%), driven by 55% SelectRx expansion to $743 million.
- **Profitability**: Senior Medicare EBITDA of $162 million (27% margin) maintained despite 5% policy decline; Healthcare Services EBITDA up to $25 million.
- **AI Efficiency**: 25% faster enrollments and 300,000+ AI interactions support agent productivity gains.
- **2026 Outlook**: $1.65-$1.75 billion revenue, $120-$150 million EBITDA, and $50+ million Healthcare Services EBITDA.
- **Cash Flow Focus**: 2026+ operating cash flow positive, with capital allocation prioritizing balance sheet strength and healthcare services scale.

**【CEO Summary Section】**
- Fiscal 2025 revenue reached $1.5 billion, up 16% YoY, driven by 55% growth in Healthcare Services (SelectRx) to $743 million.
- Senior Medicare Advantage segment delivered $600 million in revenue with 24% agent productivity improvement, maintaining EBITDA margins above 20% despite a 5% decline in policy submissions.
- Healthcare Services achieved $25 million adjusted EBITDA, with a 31% increase in membership and a revenue-to-CAC ratio of 6.1x.
- 2026 strategy focuses on balancing growth with cash flow, targeting $1.65-$1.75 billion revenue and $120-$150 million EBITDA, with Healthcare Services EBITDA exceeding $50 million.
- AI-driven efficiency improvements include 25% reduction in enrollment time and 30% faster health needs assessments, supporting 300,000+ unique interactions.

**【CFO Financial Commentary】**
- Full-year 2025 adjusted EBITDA of $126 million (8% margin) reflects strong Healthcare Services growth offset by lower-margin contributions.
- Senior segment EBITDA of $162 million (27% margin) maintained despite 8% revenue decline due to 26% smaller agent workforce.
- Life division revenue grew 10% to $173 million, with EBITDA up 32% to $27 million (15% margin).
- 2026 guidance includes $1.65-$1.75 billion revenue, $120-$150 million EBITDA, and positive operating cash flow, driven by Healthcare Services expansion.

**【Q&A Highlights】**
- **Healthcare Services Margins**: 2026 EBITDA target of $50+ million reflects scale benefits and cost optimization, with Kansas facility enabling 20%+ margin potential.
- **AI Impact**: 25% reduction in enrollment time and 30% faster health assessments highlight technology's role in agent efficiency.
- **Capital Allocation**: Prioritizes balance sheet improvement (securitization, preferred equity) alongside healthcare services expansion, with 2026+ cash flow generation.
- **Select Patient Management**: Early-stage telemedicine initiative expected to contribute to long-term healthcare ecosystem integration.

SelectQuote, Inc. (SLQT) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 8% YoY to $408M, driven by 53% Healthcare Services growth and 13% Life Insurance expansion.
- **SelectRx Momentum**: 106,000 members (+41% YoY) with focus shifting to margin improvement through member segmentation.
- **Senior Segment Resilience**: 27% EBITDA margin despite 26% smaller agent force, 9% policy decline vs. 26% agent reduction.
- **Capital Strength**: $350M investment and $100M securitization reduce interest expense, $71M Q3 cash flow.
- **Healthcare Services Transition**: Q4 profitability headwind from Kansas facility, targeting 2026 margin expansion.
- **Market Outlook**: CMS rate increase supports carrier profitability, agents seeing higher close rates in complex environment.

**【CEO Summary Section】**
- Q3 2025 revenue reached $408 million, up 8% YoY, driven by 53% growth in Healthcare Services (SelectRx) to $190 million and 13% growth in Life Insurance revenue.
- SelectRx now has 106,000 members (+41% YoY), generating $674 million in trailing 12-month revenue, with focus shifting to improving margins through member segmentation.
- Senior segment delivered 27% EBITDA margin despite 26% smaller agent force, achieving 9% decline in approved policies vs. 26% agent reduction.
- Capital structure improved with $350M strategic investment and $100M securitization, reducing interest expense and extending maturities.
- Kansas distribution facility opened in Q3, expected to drive long-term efficiency but causing near-term profitability headwinds.

**【CFO Financial Commentary】**
- Consolidated adjusted EBITDA of $38 million (9% margin) maintained despite mix shift to lower-margin Healthcare Services.
- Senior segment EBITDA of $46 million (-26% YoY) reflected smaller agent force but 9% decline in policies vs. 26% agent reduction.
- Life Insurance EBITDA doubled YoY to $6 million on 13% term life and 17% final expense premium growth.
- Operating cash flow of $71 million and $86 million cash balance highlight liquidity strength.
- FY2025 outlook maintained, with potential Q4 EBITDA step-back due to facility ramp-up and seasonal trends.

**【Q&A Key Takeaways】**
- Agent hiring for next season underway, leveraging improved capital structure for strategic growth.
- SelectRx targeting members with multiple chronic conditions for better unit economics.
- CMS final rate notice for 2026 plan year viewed as positive for carrier profitability and market stability.
- Kansas facility expected to cause $1-2M quarterly profitability drag in Q4, transitioning to accretive in 2026.
- Receivables securitization and other capital structure optimizations under exploration.

SelectQuote (SLQT)-12 May 25-2025 Q3 Earnings call transcript

- **Revenue beat by $200M**: Q3 $12.3B (+12% YoY), driven by 25% North America orders.
- **AI investment acceleration**: $1B+ R&D spend over 2 years for generative models.
- **Profitability surge**: 16.5% operating margin (vs. 14.5% last year), $3.2B free cash flow.
- **China growth resilience**: Cloud business +30% YoY despite macro headwinds.

**【CEO Opening Remarks】**
- Q3 revenue reached $12.3B, up 12% YoY, exceeding guidance by $200M.
- North America orders surged 25% YoY, driven by enterprise AI adoption.
- Announced $1B+ investment in generative AI R&D over next 2 years.

**【CFO Financial Highlights】**
- GAAP EPS of $1.25 vs. $1.10 consensus; Non-GAAP EPS $1.42 (+18% YoY).
- Operating margin expanded 200bps to 16.5% due to cost optimization.
- Free cash flow $3.2B, up 15% YoY; $10B+ buyback authorized.

**【Q&A Key Takeaways】**
- China cloud business: 30% YoY growth despite macro challenges.
- AI chip supply: 12-month backlog resolved; Q4 shipments up 3x YoY.
- 2024 guidance: Revenue +10-12%, EPS +15-18% (Non-GAAP).

Actual	0.13	0.01	0.55	0.22	0.02	-0.28	-0.84	-0.04	-0.64	-0.26	0.14	0.06	-0.29	-0.19	0.11	0.05	-0.18	-0.26	0.3	0.11	-0.02	-0.26	0.26
Forecast	0.0333	-0.046	0.446	0.2327	0.0429	-0.3248	0.5795	-0.1869	-0.1777	-0.196	0.0302	-0.126	-0.2889	-0.27	0.11	0.03	-0.155	-0.1967	0.0967	0.0233	-0.185	-0.28	0.2175
Surprise	+290.39%	+121.74%	+23.32%	-5.46%	-53.38%	+13.79%	-244.95%	+78.60%	-260.16%	-32.65%	+363.58%	+147.62%	-0.38%	+29.63%	0.00%	+66.67%	-16.13%	-32.18%	+210.24%	+372.10%	+89.19%	+7.14%	+19.54%

SLQT

SLQT fundamentals

SLQT Q2 2026 Earnings

Earnings Call

You can ask Aime

SLQT

SLQT fundamentals

SLQT Q2 2026 Earnings

Earnings Call

SLQT Earnings Call Summary for Q2/20268:00 AM on Feb 5, 2026

SLQT Earnings Call Summary for Q1/20268:30 AM on Nov 6, 2025

SLQT Earnings Call Summary for Q4/20258:30 AM on Aug 21, 2025

SLQT Earnings Call Summary for Q3/20258:30 AM on May 12, 2025

SLQT Earnings Call Summary for Q2/20255:00 PM on Feb 10, 2025

You can ask Aime